Thinking through Kierkegaard is a critical evaluation of Søren Kierkegaard's vision of the normatively human, of who we are and might aspire to become, and of what Mehl calls our existential identity. Through a pragmatist examination of three of Kierkegaard's key pseudonymous "voices" (Judge William, Climacus, and Anti-Climacus), Peter J. Mehl argues that Kierkegaard's path is not the only end of our search, but instead leads us to affirm a plurality of paths toward a fulfilling existential identity. Contrary to Kierkegaard's ideal of moral personhood and orthodox Christian identity, Mehl aims to acknowledge the possibility of pluralism in existential identities. By demanding sensitivity to the deep ways social and cultural context influences human perception, interpretation and self?representation, Mehl argues that Kierkegaard is not simply discovering but also participating in a cultural construction of the human being. Drawing on accounts of what it is to be a person by prominent philosophers outside of Kierkegaard scholarship, including Charles Taylor, Owen Flanagan, Alasdair MacIntyre, and Thomas Nagel, Mehl also works to bridge the analytic and continental traditions and reestablishes Kierkegaard as a rich resource for situating moral and spiritual identity. This reexamination of Kierkegaard is recommended for anyone interested in what it means to be a person.
With an emphasis on the fundamental and practical aspects of ADME for therapeutic proteins, this book helps readers strategize, plan and implement translational research for biologic drugs. • Details cutting-edge ADME (absorption, distribution, metabolism and excretion) and PKPD (pharmacokinetic / pharmacodynamics) modeling for biologic drugs • Combines theoretical with practical aspects of ADME in biologic drug discovery and development and compares innovator biologics with biosimilar biologics and small molecules with biologics, giving a lessons-learned perspective • Includes case studies about leveraging ADME to improve biologics drug development for monoclonal antibodies, fusion proteins, pegylated proteins, ADCs, bispecifics, and vaccines • Presents regulatory expectations and industry perspectives for developing biologic drugs in USA, EU, and Japan • Provides mechanistic insight into biodistribution and target-driven pharmacokinetics in important sites of action such as tumors and the brain
This will help us customize your experience to showcase the most relevant content to your age group
Please select from below
Login
Not registered?
Sign up
Already registered?
Success – Your message will goes here
We'd love to hear from you!
Thank you for visiting our website. Would you like to provide feedback on how we could improve your experience?
This site does not use any third party cookies with one exception — it uses cookies from Google to deliver its services and to analyze traffic.Learn More.